Two Further Substantial Contracts for PRM
Proteome Sciences plc has announced the securing of two substantial Good Clinical Laboratory Practice (GCLP) contracts with a combined value exceeding $1.5 million, with the majority of the work expected to be completed in 2026 and trial samples anticipated to ship in late Q1. This news follows a previous announcement and indicates strong demand from major biopharma clients in the US and Europe, contributing to a robust order book for the company throughout 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your PRM notes
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Two further substantial contracts for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that following the Company's announcement dated 8 December 2025, the Company has secured two further substantial Good Clinical Laboratory Practice ("GCLP") contracts. The contracts have a combined value in excess of $1.5m. Trial samples are expected to be shipped in late Q1 this year, with the major part of the contracts completed in 2026.
Commenting on the contracts, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:
"We continue to experience strong interest in GCLP work from major biopharma clients in both the US and Europe and expect further orders to materialise in due course. These new contracts together with contracts previously secured provide a strong order book supporting our business through 2026."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.